Tag: genomics
-
Trial Testing Point-of-Care Covid-19 Diagnostic
A clinical trial in the U.K. is assessing a testing device to detect Covid-19 viruses in nasal swab samples that returns results in an hour.
-
Start-Up Developing Inside-Cell Delivery, Gains $28.5M
A new company spun-off from Harvard University is developing techniques for delivering advanced genetic and protein therapies directly inside cells.
-
Gene Therapy Production Company Opens, Raises $40M
A new enterprise developing and manufacturing gene therapies, both its own and for others, is underway, raising $40 million in venture funds.
-
New Company Offers A.I. Aging Biomarker Analysis
A new enterprise is underway using artificial intelligence to analyze a person’s body chemistry and calculate the likelihood of age-related diseases.
-
Univ. Lab Discovers, Licenses Citrus Disease Treatment
Plant scientists in California discovered a natural peptide that stops bacteria from causing citrus greening, a disease destroying citrus crops worldwide.
-
Crispr Heart Therapy Demonstrated in Monkeys
An experimental therapy using a precise gene editing technique is shown in lab monkeys to reverse the cause of a chronic form of heart disease.
-
Engineered Immune, Stem Cells Studied for HIV Cure
Academic and industry researchers are investigating engineered immune-system cells combined with stem cells as an immunotherapy to neutralize HIV viruses and cure infections.
-
Biotechs Partner on Crispr for Stem Cell Transplants
A biotechnology partnership is evaluating a synthetic antibody to make it safer for people with genetic diseases to receive gene-edited bone marrow stem-cell transplants.
-
Covid-19 Antibody Cocktail to Begin Clinical Trial
A combination of two synthetic antibodies, with an enhanced infection-blocking design for preventing and treating Covid-19 infections, is set to begin a clinical trial.
-
Crispr Heart Disease Start-Up Raises New $63M
A one year-old company developing a one-time gene-editing treatment for coronary artery disease is adding $63 million to its first venture funding round.